Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Monopar Therapeutics Inc (1IY0) Stock Price & Analysis

0 Followers

1IY0 Stock Chart & Stats

€63.80€0.60(9.25%)
At close: 5:30 PM GMT+1
€80€85€90€95Jun 29Jul 9
Day’s Range
EUR 63.80 - EUR 64.50
52-Week Range
EUR 41.70 - EUR 103.40
Previous Close
EUR 58.40
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 431.38M
Enterprise Value
EUR 656.75M
Total Cash (Recent Filing)
EUR 134.30M
Total Debt (Recent Filing)
EUR 107.83K
Price to Earnings (P/E)
―
Beta
9.72
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Capital Base

Extremely low leverage reduces financial risk and preserves flexibility while Monopar advances its pipeline. The sizable equity and asset base provides a stronger funding foundation than earlier periods, although continued losses could erode that support if external financing remains necessary.

FDA NDA Progress For ALXN1840

Beginning a rolling NDA submission represents meaningful advancement from clinical development toward potential regulatory review and commercialization. If the process progresses successfully, ALXN1840 could create a future product-based revenue opportunity and reduce reliance on financing-driven funding.

Rare Pediatric Disease Designation

FDA Rare Pediatric Disease designation is a tangible regulatory milestone that supports the development path for ALXN1840 and may provide regulatory incentives. It strengthens the program's strategic position and reinforces progress toward a potential future commercial product.

Bears Say

No Commercial Revenue

The absence of reported revenue shows that Monopar has not yet established a commercial product stream to fund operations. Until a candidate is approved and generates sales, the company remains dependent on development progress and external capital rather than recurring operating income.

Widening Net Losses

Widening losses indicate that spending has increased without offsetting commercialization in the reported periods. Persistent negative earnings can consume the company's capital base and increase the amount of financing required before pipeline programs can potentially generate sustainable revenue.

Persistent Cash Burn

Consistently negative operating and free cash flow means the business is not internally funding its development activities. Even excluding the reported TTM anomaly, prior annual cash outflows show continued reliance on external capital, creating funding pressure until cash generation improves.

Monopar Therapeutics Inc News

1IY0 FAQ

What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was €41.70 and its highest was €103.40 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is €431.38M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s next earnings report is estimated for Nov 06, 2026 (not yet confirmed), which is 5 days ago.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -€0.555 earnings per share for the quarter, beating the consensus estimate of -€0.579 by €0.024.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.74.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,712,172 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -€0.555 in its last earnings report, beating expectations of -€0.579. Following the earnings report the stock price went down -8.464%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Hedge funds hold Monopar Therapeutics Inc shares: the largest hedge-fund position in Monopar Therapeutics Inc is 2,125,030,672 shares, and hedge funds increased their holdings by 50.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology